The pandemic has revealed many health inequities across society. A panel of speakers at MedCity News’ INVEST Pop Health conference discussed the various ways that they are working to reduce inequities and improve outcomes.
To succeed in population health, companies must first consider the basics, such as wrangling patient data and making sure it matches up. Panelists at INVEST Pop Health spoke about the challenges of taking this information and translating it into meaningful health outcomes.
Real-world data has long been touted as the solution to many challenges faced in the healthcare space – but more data doesn’t necessarily mean more answers. RWD has become the lynchpin to a more patient-centric approach to care, from drug development to therapy access and provider engagement. But until the tools and technology are in place to turn that data into actionable insights, in context, they’re nothing but numbers. Join us for a discussion on the crucial role of real world data and advanced analytics in the digital transformation of the life sciences industry.
In a Spotlight Video interview, Fredrikson & Byron Shareholders and Co-chairs of the firm's life sciences group, Jeff Steinle and Ryan Johnson, talked about the deal-making environment in healthcare and how the Covid-19 pandemic has impacted it.
Life sciences companies are using “digital twins” for everything from drug discovery to manufacturing. A panel of experts at MedCity News’ INVEST Digital Health conference discussed how this capability to run virtual simulations is changing practices now while also shaping the industry for the years to come.
The reimbursement model for remote patient monitoring needs to evolve as it may be holding providers back from investing in these programs, according to panelists at the MedCity INVEST Digital Health conference. Key issues with the structure as it stands now include the fact that there are too many gray areas that result in claims denials.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
As Google and Microsoft compete over their cloud capabilities for healthcare, both companies are touting tools to make clinicians’ lives easier by streamlining documentation or making records searchable. At MedCity INVEST Digital Health, executives from both companies agreed on one thing: these tools should play a supporting role for clinicians while keeping patients at the center.
Algorithms are everywhere and so are the biases behind them. As algorithms find greater use in healthcare, a panel at MedCity News’ INVEST Digital Health virtual conference addressed how and why algorithms are biased, how that bias affects clinical care, and some possible solutions to bias.
VCs at MedCity INVEST Digital Health said there’s no shortage of interesting digital health companies, even ones that can prove their innovations are effective. The challenge is winning over insurers and physicians, and finding payment models that work.
Leaders with insurers and health systems said that taking a holistic approach and partnering with community organizations is key to standing up a successful social determinants of health program at a panel discussion hosted by MedCity INVEST Digital Health.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Consumers want the healthcare industry to meet them where they are, and this shift in patient mindset has expanded the definition of home healthcare and who benefits from it, according to a panel at MedCity INVEST Digital Health conference.
Experts in precision medicine provide a broad overview of where we are and where we need to go to make the promise and potential of this sector a reality.
A panel discussion on non dilutive funding sources for biopharma and medtech startups from government research and industry grants to industry partnerships and venture debt.
This panel highlights how different organizations in the biopharma supply chain are addressing the inherent challenges of producing and delivering cell and gene therapies and biologics.
This panel explores some of the diverse approaches companies are taking to improve efficiency and avert pitfalls in therapeutic development.
